$200K — $250K *
89bio is a clinical-stage biopharmaceutical company focused on rapidly advancing our lead product candidate, BIO89-100, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH). BIO89-100 is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). It may be a differentiated FGF21 therapy, and we believe it has the potential to become a mainstay of therapy for NASH given its ability to address the key liver pathologies (steatosis and fibrosis) and underlying metabolic dysregulation in patients with NASH.
We are also expanding the breadth of indications for BIO89-100 with an initial focus on severe hypertriglyceridemia (SHTG).Hypertriglyceridemia is characterized by elevated levels of triglycerides (a type of lipid). When levels of triglycerides are severely elevated (≥500 mg/dL), the condition is known as SHTG and is associated with an increased risk of NAFLD, NASH, and cardiovascular diseases, as well as acute pancreatitis. It is estimated that there are 2.5 million to 4 million patients in the US with triglyceride levels ≥500 mg/dL. Of these patients, it is estimated that 42% have dyslipidemia and 27% have diabetes. This patient population is expected to increase due to the triple epidemic of obesity, metabolic syndrome, and Type 2 diabetes. A large portion of these patients are unable to achieve treatment goals with existing therapies. In third-party studies, up to 50% of treated SHTG patients were unable to reduce their triglyceride levels to
89bio is headquartered in San Francisco with operations in Herzliya, Israel. The Company recently closed its upsized initial public raising a gross $97.6 million.
Reporting to the Chief Medical Officer, the Vice President/Senior Medical Director* Clinical Development will have lead responsibility for the SHTG program, planning and implementing the Company's new indication. She/he will collaborate with key internal and external stakeholders to support company initiatives that improve the quality and content of all clinical programs to deliver our portfolio. The position is based in our San Francisco office and requires some domestic and international travel.
*Title commensurate with experience.
REQUIRED EDUCATION, SKILLS & EXPERIENCE
Valid through: 10/6/2020
$200K — $250K
44 days ago
$100K — $150K
22 days ago